Investors Back Asceneuron To Rival Lilly In Alzheimer’s Oral Drug Class

 
• By Andrew McConaghie
  
Tau Alzheimer's disease
Pathological phosphorylation of Tau proteins leads to disintegration of microtubuli in an axon and to aggregation of the tau proteins. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip